Page 113 - Bio Engineering Approaches to Cancer Diagnosis and Treatment

References 111

cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell
lymphoma patients: a phase II clinical trial. Am. Soc. Hematology, (2016).
[53] K.L. Knutson, R. Clynes, B. Shreeder, P. Yeramian, K.P. Kemp, K. Ballman, D.J.C.r.
Northfelt, Improved survival of HER2+ breast cancer patients treated with trastuzumab
and chemotherapy is associated with host antibody immunity against the HER2 intracel-
lular domain, Cancer Res. 76 (13) (2016) 3702–3710.
[54] J. Corral, M. Majem, D. Rodríguez-Abreu, E. Carcereny, A. Cortes, M. Llorente, & T.
Oncology. Efficacy of nintedanib and docetaxel in patients with advanced lung adeno-
carcinoma treated with first-line chemotherapy and second-line immunotherapy in the
nintedanib NPU program. (2019), 1–10.
[55] P.J. Carter, G.A. Lazar, Next generation antibody drugs: pursuit of the’high-hanging
fruit’, Nat. Rev. Drug Dis. 17 (3) (2018) 197.
[56] R.V. Chari, M.L. Miller, W.C. Widdison, Antibody–drug conjugates: an emerging con-
cept in cancer therapy, Angewandte Chemie Int. Ed. 53 (15) (2014) 3796–3827.
[57] S.C. Alley, N.M. Okeley, P.D. Senter, Antibody–drug conjugates: targeted drug delivery
for cancer, Curr. Opin. Chem. Biol. 14 (4) (2010) 529–537.
[58] C. Chalouni, S. Doll, Fate of antibody-drug conjugates in cancer cells, J. Exp. Clin. Can.
Res. 37 (1) (2018) 20.
[59] P. Ehrlich, Address in pathology, on chemiotherapy: delivered before the Seventeenth
International Congress of Medicine, Brit. Med. J. 2 (2746) (1913) 353.
[60] N. Diamantis, U. Banerji, Antibody-drug conjugates—an emerging class of cancer treat-
ment, Brit. J. Can. 114 (4) (2016) 362.
[61] P.A. Trail, G.M. Dubowchik, T.B. Lowinger, Antibody drug conjugates for treatment of
breast cancer: novel targets and diverse approaches in ADC design, Pharma. Therap. 181
(2018) 126–142.
[62] J.M. Lambert, A. Berkenblit, Antibody–drug conjugates for cancer treatment, Ann. Rev.
Med. 69 (2018) 191–207.
[63] K. Tsuchikama, Z. An, Antibody-drug conjugates: recent advances in conjugation and
linker chemistries, Protein Cell 9 (1) (2018) 33–46.
[64] K. Starbuck, L. Al-Alem, D.A. Eavarone, S.F. Hernandez, C. Bellio, J.M. Prendergast, J.
Behrens, Treatment of ovarian cancer by targeting the tumor stem cell-associated carbo-
hydrate antigen, sialyl-thomsen-nouveau, Oncotarget 9 (33) (2018) 23289.
[65] K. Garber. Cancer stem cell pipeline flounders (2018).
[66] F. Marcucci, E.L. Romeo, C.A. Caserta, C. Rumio, Antibody-drug conjugates (ADC)
against cancer stem-like cells (CSC)–is there still room for optimism? Front. Oncol. 9
(2019) 167.
[67] V. Chudasama, A. Maruani, S. Caddick, Recent advances in the construction of antibody–
drug conjugates, Nat. Chem. 8 (2) (2016) 114.
[68] J.M. Connors, W. Jurczak, D.J. Straus, S.M. Ansell, W.S. Kim, A. Gallamini, E. Lech-
Maranda, Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lym-
phoma, New Engl. J. Med. 378 (4) (2018) 331–344.
[69] E.M. Stein, R.B. Walter, H.P. Erba, A.T. Fathi, A.S. Advani, J.E. Lancet, S. Faderl, A
phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive
acute myeloid leukemia, Blood 131 (4) (2018) 387–396.
[70] R. Zhang, M.M. Billingsley, M.J. Mitchell, Biomaterials for vaccine-based cancer im-
munotherapy, J. Control. Release 2 (2018) 256–276.
[71] S.T. Koshy, D.J. Mooney, Biomaterials for enhancing anti-cancer immunity, Curr. Opin.
Biotech. 40 (2016) 1–8.